The gene synthesis market is set to reach US$ 11.23 BN by 2032, at a 19.96% CAGR between years 2023-2032. The forces that govern the dynamic forces of gene synthesis market are a combination of scientific innovation, medical need, industry process and dual economy related to its customized genetic content. The synthetic genomes present the breathtaking landscape with their growing requirement in different industries.
With the artificial approach to DNA sequences that is applied in various industries, such as biotechnology, pharmaceuticals, academic researches, and agriculture gene synthesis may be named. More focus should be on the growing diversity of synthetic biology and genetic engineering, which is the main factor in this market’s movement.
Gene synthesis serves as a tool that is systematically utilized by the researchers and the industries to organize DNA sequences for various applications such as production of therapeutic proteins, developing genetically modified organisms etc. Technological developments such as the advancement of gene synthesis have a central position in determining the dynamics of the market.
With constant evolutions in the field of DNA synthesis technologies, accuracy adjustments, scaling up or down as required and cost fructifications that have led to availability and acceptance thereof has become a reality. The progress in the development of modern high-throughput synthesis techniques enables to produce custom DNA constructs at a significantly faster rate than before and is sufficient now due to the growing use of synthetic genes today.
The dynamics in the gene synthesis market is strongly influenced by its relationship with healthcare. Gene therapy, molecular diagnostics that can be tailored to specific patients; and personalized medicine are premised obviously on the success of accurate de novo DNA synthesis. The development of personalized gene constructs for use in vector pharmaceuticals is made possible by synthetic genes, but they also contribute to the field of precision medicine’s progress.
One of the most important forces to consider in the gene synthesis market is regulation. The handle on genomic material carries ethical interference and danger issues that will lead to the development of regulatory structure that could govern constructed genetic synthesis activities. As an important example of the aspects on which companies that provide gene synthesis services should focus, these regulations must be strictly followed obliging them to adjust for their operating procedures, quality control measures and even the whole market environment.
Fiscal factors that significantly influence the gene synthesis market include research funding, trading investment and markets’ demand. Public and private funding grants the projects of synthetic biology based on gene synthesis is carried out, which allows making progress in such practical directions as focus on customized genetic materials to make atypical connections between cells. Investment in gene synthesis companies acts to stimulate technological innovation and, therefore increase the competitiveness of the industry.
The process of globalization, inter-institutional collaboration that is deftly articulated among research institutions biotechnology companies and academic organizations in addition to non-governmental formations reconcile into the dimensioning of gene synthesis market. Duality of International cooperation and intricacy the development advancement through cross-border partnerships enables easier transfer of knowledge, resources, and proven models to accelerate synthetic biology innovations.
Report Attribute/Metric | Details |
---|---|
Segment Outlook | Method, Services, Application, End User, and Region |
The Gene Synthesis Market size was valued at USD 1.82 billion in 2022 and is projected to grow from USD 2.18 billion in 2023 to USD 11.23 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 19.96% during the forecast period (2023 - 2032). The increased biopharmaceutical research, growing demand for customized genetic constructs, and the rise of academic and government research institutes engaged in genomics and genetic engineering projects are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Academic and government research institutes are increasingly adopting gene synthesis services to finish genomics projects, genetic engineering research, and fundamental science studies. The potential of the industry has grown as more diverse end customers are now looking for gene synthesis solutions. Collaboration and partnership agreements are fostering innovation and broadening the selection of services provided for gene synthesis by academic institutions, biotechnology companies, and contract research organizations. These collaborative efforts are accelerating research and product development across several industries.
Furthermore, government and academic research organizations employ these services for their genomics and genetic engineering projects which boost the growth of market.
The Market segments of Gene Synthesis, based on method, includes solid-phase synthesis, chip-based DNA synthesis, and PCR based enzyme synthesis. The solid-phase synthesis segment is held the majority share in 2022 in the Gene Synthesis Market revenue. This is due to the increasing adoption rate during the past few years. Additionally, Solid phase synthesis is also being employed more frequently due to its various advantages, such as its speedy production of linear peptide intermediates, ease of purification, and proficiency in the synthesis of large peptides.
January 2023: Astellas (Japan) and Twist Bioscience (US) collaborate on multitarget antibody discovery research. Through this tactical partnership, Twist Bioscience hope to find therapeutic antibodies for patients with diseases for which there are currently no effective treatments. This tactic is anticipated.
The Market segmentation of Gene Synthesis is based on a services, that includes, antibody DNA synthesis, viral DNA synthesis, and others. The antibody DNA synthesis segment has dominated the market in 2022 and the intramuscular segment is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the increased revenue from the synthesis of genes, increased cloning, and increased chemical synthesis of the genes. Moreover, antibody DNA synthesis helps researchers create a synthetic copy of the gene that codes for a particular antibody that can be produced in a host organism or in vitro system, which is particularly helpful for producing huge amounts of a particular antibody.
Figure 2: Gene Synthesis Market, by services, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Market segmentation of Gene Synthesis, based on application, includes protein engineering, vaccine design & development, disease diagnosis, therapeutic antibodies, and others. The protein engineering segment held the majority share in 2022 in the Gene Synthesis Market revenue. This is due to rising research and development efforts to create novel proteins for various applications.
The Gene Synthesis Market segmentation of Gene Synthesis is based on the end user that includes biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. The academic & government research institutes segment has dominated the market in 2022 and Contract research organizations is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to the increased government financing for chronic disease research and development, along with more advancements in gene therapy, as well as more research and development. Moreover, academic and government research institutes utilize these services for genomics projects and genetic engineering studies.
November 2021: GenScript (US) expanded Manufacturing Capabilities for gene synthesis in the USA. With this expansion, GenScript will be able to synthesize 200 genes per day in the fully automated facility, serving more clients and completing more difficult gene projects. With an increased capacity to synthesize 4,000–5,000 genes per month in the US, this new facility provides a much improved capacity to manage large gene synthesis projects.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American gene synthesis market accounted for the largest market share in 2022. This is attributed to the growing research and development efforts and new gene-based inventions together with an expanded market for gene synthesis Along with an increase in chronic diseases is gene therapy. Additionally, rising research activity for the creation of efficient treatments and growing interest in synthetic biology research in the region will both significantly expand the market forecast.
Further, the major countries studied are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Figure 3: Gene Synthesis Market by region, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe gene synthesis market is expected to account for the second-largest market share due to the Growing gene synthesis use in creating tailored medications and expanding applications of the method in synthetic biology in the region. Further, the France market of gene synthesis was attributed to holding the largest market share, and the Germany market of gene synthesis is expected to fastest-growing market in the European region.
The Asia-Pacific gene synthesis market is expected to grow at the fastest rate from 2023 to 2032. This is due to the rising interest in synthetic biology research as well as expanding research efforts to create efficient treatments in the Asia-pacific region. Moreover, China’s market of gene synthesis is expected to hold the largest market share, and India market of gene synthesis is expected fastest-growing market in the Asia-Pacific region.
Furthermore, the gene synthesis industry is expanding quickly in the Asia-Pacific region, which includes countries like China and India. The PCR-based enzyme synthesis approach is still useful, especially for economical solutions, even if solid-phase synthesis and chip-based DNA synthesis are gaining popularity. The region's expanding biotechnology and pharmaceutical sectors, coupled with increasing research investments which is expected to accelerate the market growth in the gene synthesis.
The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of gene synthesis in the Middle East and Africa are the expanding research activities and biotechnology endeavors in the region that boost the market growth in the Middle East. Moreover. The landscape of gene synthesis in these areas is gradually changing as a result of initiatives to enhance the availability of healthcare services and research resources. On the other hand, the growth opportunities in developing countries such as South Africa, UAE, and Saudi Arabia are estimated to provide lucrative growth opportunities to the market players.
Gene Synthesis Key Market Players & Competitive Insights
The Gene Synthesis Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Thermo Fisher Scientific, Inc (US), GenScript (US), Eurofins Genomics (US), and Integrated DNA Technologies, Inc. (US) dominate the Gene Synthesis Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global gene synthesis industry to benefit clients and expand the gene synthesis market sector is to manufacture locally to reduce operating costs.
Eurofins Genomics (US) is a leading European provider of genomics services. It stands out for its commitment to quality assurance and stringent regulatory compliance. The business provides clinical diagnostic testing, DNA/RNA synthesis, DNA sequencing, gene synthesis, bio-analytical services, and clinical diagnostic testing for academic and commercial research institutes. The company has operations in the US, Europe, and Asia. For instance, in August 2019, Eurofins Genomics (US) acquired Blue Heron Biotech (US), a business that specializes in complicated gene synthesis. The combination of their three core product categories sequencing, synthetic genes, and oligonucleotides—improves Eurofins Genomics' synthetic biology offering and provides synergy for both businesses.
Also, Thermo Fisher Scientific, Inc (US) is a prominent player known for its wide array of life science products and services. The company continuously invests in gene synthesis technologies, offering high-quality synthetic genes. It sells its items and offerings directly to consumers, online, and through third parties in the Americas, Asia-Pacific, and Europe. Moreover, collaborations with academic and pharmaceutical institutions strengthen its position in the market.
Key Companies in the Gene Synthesis Market include
Gene Synthesis Industry Developments
December 2020: Twist Bioscience (US) introduced Clonal-Ready Gene Fragments, a full solution for customers. Build structures using the top Gene Fragments from Twist, both with and without adapters, to save time and money searching for the best clones. Gene fragments are created using the reliable silicon platform from Twist Bioscience, which is based on semiconductors.
September 2022: GenScript (US) and Avectas (US) Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process. Together, the two businesses hope to offer their clients cutting-edge, innovative approaches for creating cell therapies that are less dangerous than viral and non-viral vectoring techniques.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)